Ann: Positive CE Mark Status Report, page-41

"In July OncoSil submitted detailed responses to the BSI, including updated and new clinical data and testimonials from “leading, pre-eminent experts in medical oncology, radiation oncology and Hepato-Pancreato-Biliary surgery”.
It met with the BSI in early October and reported positive preliminary discussions, which sent shares moving upwards.
The CE Mark review now progresses to its final phase, assessing plans outlining how the OncoSil device would be rolled out by OncoSil into the European Market.
Daniel Kenny, OncoSil’s CEO, says his company will present its detailed plans in mid-November. “Receiving confirmation that OncoSil has closed out concerns raised earlier this year by BSI is very gratifying,” he said.